Description
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
Overview
Clone REA316 recognizes the human CD100 antigen, a single-pass type I membrane protein which is also known as semaphorin-4D (SEMA4D). CD100 is strongly expressed in skeletal muscle, and at lower levels in testes, brain, kidney, small intestine, prostate, heart, placenta, lung, and pancreas. In the immune system, it is present on peripheral blood lymphocytes, spleen, and thymus, especially interfollicular T cells and B cells in the germinal centers of secondary lymphoid follicles. CD100 is an axon guidance molecule which is secreted by oligodendrocytes and induces growth cone collapse in the central nervous system. By binding plexin B1 receptor it functions as an R-Ras GTPase-activating protein and repels axon growth cones in the central nervous system. In the immune system, CD100 plays a critical role by turning off negative signaling by CD72 and significantly enhancing the effects of CD40 on B cell and dendritic cell responses. During skin damage repairs, SEMA4D interacts with plexin B2 on gamma delta T cells to play a role in the healing process.
Additional information: Clone REA316 displays negligible binding to Fc receptors.
